trending Market Intelligence /marketintelligence/en/news-insights/trending/tdahwy8cqcgft5iqgbtzog2 content esgSubNav
In This List

Indivior loses patent suit to Alvogen for opioid addiction therapy

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Indivior loses patent suit to Alvogen for opioid addiction therapy

Indivior PLC said a U.S. court found that privately held Alvogen, Inc. did not violate three of the patents related to its opioid addiction therapy, Suboxone Film.

The Richmond, Va.-based pharmaceutical company "believes that it has grounds to appeal" the U.S. District Court for the District of Delaware's ruling on the patents.

According to the company's 2017 annual report, Suboxone Film had an average market share of 57% in 2017, down from 61% in 2016.

Indivior added that if a generic version of Suboxone Film should be released in the U.S., "it could potentially result in a rapid and material loss of market share" for the medicine.

In February, Indivior filed lawsuits in the U.S. against generic-drug makers Dr. Reddy's Laboratories Ltd., Alvogen and Teva Pharmaceutical Industries Ltd. over a patent covering the opioid addiction treatment.